Skip to main content

Table 1 Patient and tumor characteristics

From: Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors

 

Total

Percentage

Number of patient samples

 Total

801

100

Age

 Mean ± SD

62.25 ± 13.7

 

 Median (range)

63 (22–90)

Tumor size

 <2 cm

400

49.9

 ≥2–5 cm

358

44.7

 >5 cm

43

5.4

Histology

 Ductal

638

79.7

 Lobular

118

14.7

 Other

45

5.6

Tumor stage

 T1

413

51.6

 T2

342

42.7

 T3

38

4.7

 T4

8

1

Grade

 I

91

11.4

 II

502

62.7

 III

208

26

Nodal status

 N0

492

61.4

 N1

226

28.2

 N2

51

6.4

 N3

32

4

Menopausal status

 Premenopausal

167

20.8

 Perimenopausal

51

6.4

 Postmenopausal

583

72.8

Receptor status

 ER+

681

85

 ER-

120

15

 PgR+

563

70.3

 PgR-

238

29.7

 HER2+

110

13.7

 HER2-

691

86.3

 HR+

688

85.9

 HR-

113

14.1

Receptor-defined subtype

 Luminal A-like

510

63.7

 Luminal B-like (HER2 positive)

74

9.2

 Luminal B-like (HER2 negative)

104

13

 HER2 positive (non-luminal-like)

36

4.5

 TNBC

77

9.6

  1. ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2, TNBC triple negative breast cancer